Journal article
Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases
Abstract
BACKGROUND: A daily single capsule (polycap) of 3 blood pressure (BP) lowering drugs (hydrochlorthiazide, 12.5 mg; atenolol, 50 mg; ramipril, 5 mg) at low doses, simvastatin (20 mg), and aspirin (100 mg) has been demonstrated to be well tolerated and to reduce BP and low-density lipoprotein cholesterol. We examined the incremental effects of 2 (full dose) plus K(+) supplementation versus single polycap (low dose) on risk factors and …
Authors
Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK
Journal
Circulation Cardiovascular Quality and Outcomes, Vol. 5, No. 4, pp. 463–471
Publisher
Wolters Kluwer
Publication Date
7 2012
DOI
10.1161/circoutcomes.111.963637
ISSN
1941-7713
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, OralAgedAnalysis of VarianceAntihypertensive AgentsAspirinAtenololBiomarkersBlood PressureCapsulesCardiovascular DiseasesCholesterol, LDLCreatinineDietary SupplementsDose-Response Relationship, DrugDouble-Blind MethodDrug CombinationsFemaleHeart RateHumansHydrochlorothiazideHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHypertensionIndiaMaleMiddle AgedPlatelet Aggregation InhibitorsPolypharmacyPotassiumRamiprilRisk AssessmentRisk FactorsSimvastatinTabletsTime FactorsTreatment Outcome